Latest Comments

Researchers raise hope for affordable malaria diagnostics

Researchers raise hope for affordable malaria diagnostics

Agios’s enasidenib is on track to become the first IDH2 inhibitor approved in AML

Agios’s enasidenib is on track to become the first IDH2 inhibitor approved in AML

World Malaria Day 2017: focus on prevention

World Malaria Day 2017: focus on prevention

Newest class of type 2 diabetes drugs continues its push into the US market

Newest class of type 2 diabetes drugs continues its push into the US market

WHO’s first global hepatitis report aims high: elimination of hepatitis B and C by 2030

WHO’s first global hepatitis report aims high: elimination of hepatitis B and C by 2030

More than just a pretty face: Botox set to combat depression

More than just a pretty face: Botox set to combat depression

Recurring C. difficile infections cause havoc in hospitals in Scotland and England

Recurring C. difficile infections cause havoc in hospitals in Scotland and England

Curing hepatitis C: A double-edged sword for liver transplant candidates?

Curing hepatitis C: A double-edged sword for liver transplant candidates?

Small but mighty: nanotechnology in cancer therapy

Small but mighty: nanotechnology in cancer therapy

Mundipharma to market Invossa in Korea, marking another strategic partnership for Kolon Life Science

Mundipharma to market Invossa in Korea, marking another strategic partnership for Kolon Life Science

Novo Nordisk’s Refixia: what are its prospects in the hemophilia B space?

Novo Nordisk’s Refixia: what are its prospects in the hemophilia B space?

Roche’s Ocrevus expected to be a game-changer for the multiple sclerosis market

Roche’s Ocrevus expected to be a game-changer for the multiple sclerosis market

Move Over, Zika and Ebola - the next global epidemic could be metabolic

Move Over, Zika and Ebola - the next global epidemic could be metabolic

Antibiotic stewardship: can we learn from England’s C. difficile success?

Antibiotic stewardship: can we learn from England’s C. difficile success?

Pfizer seeking a timely re-launch of Mylotarg in AML amid increasing competition

Pfizer seeking a timely re-launch of Mylotarg in AML amid increasing competition

Rare diseases are a huge opportunity for pharma

Rare diseases are a huge opportunity for pharma

A chemotherapy-free future for breast cancer?

A chemotherapy-free future for breast cancer?

A brighter future for rheumatoid arthritis patients?

A brighter future for rheumatoid arthritis patients?

Liquid biopsies in melanoma – transformation of patient care tantalizingly close

Liquid biopsies in melanoma – transformation of patient care tantalizingly close

Dementia associated with soccer headers

Dementia associated with soccer headers

Low Drug Compliance in Lupus: Are Patients Really to Blame?

Low Drug Compliance in Lupus: Are Patients Really to Blame?